PEG包衣左氧氟沙星脂质体的制备及性质
Preparation and characterization of PEG coating levofloxacin-liposomes

DOI: 10.6040/j.issn.1671-7554.0.2017.339

Keywords: 硫酸铵梯度法,PEG包衣,肺靶向脂质体,稳定性,左氧氟沙星,
Levofloxacin,Pulmonary targeted liposome,Ammonium sulfate gradients method,PEG coating,Stability

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	张菁, 郁继诚, 施耀国, 等. 左氧氟沙星药代动力学/药效学研究[J]. 中华医学杂志, 2005, 27: 1926-1932. ZHANG Jing, YU Jicheng, SHI Yaoguo, et al. Study of pharmacokinetics/pharmacodymics os levofloxacin[J]. Natl Med J China, 2005, 27: 1926-1932.
[2]	Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity[J]. Expert Opin Drug Deliv, 2011, 8(5): 565-580.
[3]	Tahara K, Tomida H, Ito Y, et al. Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects[J]. Int J Pharm, 2016, 505(1-2): 139-146.
[4]	Fresta M, Spadaro A, Cerniglia G, et al. Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts[J]. Antimicrob Agents Chemother, 1995, 39(6): 1372-1375.
[5]	Ghimire S, Van't Boveneind-Vrubleuskaya N, Akkerman OW, et al. Pharmacokineti /pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB[J]. J Antimicrob Chemother, 2016, 71(10): 2691-2703.
[6]	Elborn JS, Flume PA, Cohen F, et al. Safety and efficacy of prolonged levofloxacin inhalation solution(APT-1026)treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection[J]. J Cyst Fibros, 2016, 15(5): 634-640.
[7]	Islan GA, Tornello PC, Abraham GA, et al. Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization[J]. Colloids Surf B Biointerfaces, 2016, 143(1): 168-176.
[8]	Elhissi A. Liposomes for pulmonary drug delivery: the role of formulation and inhalation device design[J]. Curr Pharm Des, 2017, 23(3): 362-372.
[9]	Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes[J]. Cancer Res, 1994, 54(4): 987-992.
[10]	Jain NK, Nahar M. PEGylated nanocarriers for systemic delivery[J]. Methods Mol Biol, 2010, 624: 221-234. doi: 10.1007/978-1-60761-609-2_15.
[11]	Zhang X, Sun P, Bi R, et al. Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation[J]. J Drug Target, 2009, 17(5): 399-407.
[12]	Gaspar MC, Gregoire N, Sousa JJ, et al. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres[J]. Eur J Pharm Sci, 2016, 93(1): 184-191.
[13]	樊菊香, 吴国球, 严雪娇, 等. 靶向左氧氟沙星脂质体的制备及其抗耐药菌作用的研究[J]. 东南大学学报(医学版), 2015, 34(1): 27-31. FAN Juxiang, WU Guoqiu, YAN Xuejiao, et al. Study on targeting levofloxacin liposome against drug-resistance bacteria and its preparation[J]. J Southeast Uni(Medical Science Edition), 2015, 34(1): 27-31.
[14]	张新科. 左氧氟沙星脂质体的肺靶向性研究[D]. 济南:山东大学, 2009.
[15]	Hussain S. Nanomedicine for treatment of lung cancer[J]. Adv Exp Med Biol, 2016, 890(1): 137-147.
[16]	Suk JS, Xu QG, Kim N, et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery[J]. Adv Drug Deliv Rev, 2016, 99(PtA): 28-51. doi: 10.1016/j.addr.2015.09.012.
[17]	Propst CN, Nwabueze AO, Kanev IL, et al. Nanoaerosols reduce required effective dose of liposomal levofloxacin against pulmonary murine Francisella tularensis subsp. novicida infection[J]. J Nanobiotechnology, 2016, 14(1): 29-38.
[18]	Dadashzadeh S, Mirahmadi N, Babaei MH, et al. Peritoneal retention of liposomes: Effects of lipid composition PEG coating and liposome charge[J]. J Control Release, 2010, 148(2): 177-186.
[19]	Lee HK, DeVito V, Vercelli C, et al. Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers[J]. Res Vet Sci, 2017, 112(1): 26-33.
[20]	Elborn JS, Vataire AL, Fukushima A, et al. Comparison of inhaled antibiotics for the treatment of chronic pseudomonas aeruginosa lung infection in patients with cystic fibrosis: systematic literature review and network meta-analysis[J]. Clin Ther, 2016, 38(10): 2204-2226.
[21]	Gong X, Wang H, Yuan Y. Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism[J]. Exp Ther Med, 2016, 12(4): 2265-2274.
[22]	Matsuse H, Oshio T, Kishimoto K, et al. A case of pulmonary mycobacterium abscessus infection that developed during immunosuppressive therapy for myasthenia gravis with recurrent thymoma[J]. Kekkaku, 2016, 91(2): 53-57.
[23]	Zaru M, Sinico C, De Logu A, et al. Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation[J]. J Liposome Res, 2009, 19(1): 68-76.
[24]	Blume G, Cevc G. Liposomes for the sustained drug release in vivo[J]. Biochim Biophys Acta, 1990, 1029(1): 91-97.
[25]	Wu NZ, Da D, Rudoll TL, et al. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue[J]. Cancer Res, 1993, 53(16): 3765-3770.

Full-Text